Plantimex Recalls Mamisan Lidocaine Ointment Containers Due to Risk of Serious Injury or Death from Child Poisoning; Violates Mandatory Standard for Child-Resistant Packaging

What was recalled

The Consumer Product Safety Commission (CPSC) has issued a recall affecting a specific line of topical pain relief products manufactured and distributed by Plantimex. The affected items are Mamisan Pain Relieving Topical Ointment jars, which were marketed as a solution for minor aches and pains. This is not a broad recall of every product made by the company, but rather a targeted action against a single SKU that failed to meet mandatory federal safety standards. If you have been using this particular ointment for muscle soreness or joint pain, it is crucial to verify exactly which version you possess, as only specific containers are subject to this safety alert.

The product in question comes packaged in a distinct 3.52-ounce plastic jar. Visually, the container is designed with an orange body and is topped with a white continuous thread lid. The branding is prominent: the Mamisan trademark is printed clearly on the top of the white lid as well as on the wraparound label that covers the side of the jar. This label includes standard drug facts and usage instructions typical for over-the-counter pain relievers. However, the critical identifier for this recall is not just the brand name or the package color, but the specific Universal Product Code (UPC) printed on the packaging. Only jars bearing the UPC code 860006498115 are included in this recall. If your jar has a different barcode number, it is likely not part of this specific safety issue.

The scope of this recall is defined by these precise physical characteristics and the unique identifier on the box or label. The CPSC action was initiated because the packaging did not comply with the Poison Prevention Packaging Act, which requires certain hazardous household substances to be packaged in child-resistant containers. While the ointment itself is a common remedy for adults, its container failed to prevent young children from opening it. This recall does not mention any specific dates of sale or geographic regions where the product was distributed, but consumers who purchased Mamisan Pain Relieving Topical Ointment in 3.52-ounce jars with the specified UPC code should treat their current stock as part of this batch. The lack of reported incidents to date does not negate the potential danger; it simply means that, so far, no poisonings have been officially documented by the agency. Nevertheless, the absence of reported harm is not an invitation to ignore the recall notice.

Understanding exactly what was recalled helps narrow down the risk and prevents unnecessary panic for owners of other Plantimex products or different sizes of Mamisan ointment. The focus here is strictly on the 3.52-ounce plastic jars with the orange container, white lid, and UPC 860006498115. If you are unsure whether your product matches this description, it is best to err on the side of caution and check the barcode carefully. This precision ensures that only those with the non-compliant packaging take action, while others can continue to use their products safely.

The hazard, explained

To understand why this recall is so urgent, we first need to look at the specific chemical involved and how it interacts with the human body, particularly a young child’s developing physiology. The recalled Mamisan Pain Relieving Topical Ointment contains lidocaine. While lidocaine is a widely used and generally safe local anesthetic for adults when applied correctly to minor cuts, scrapes, or insect bites, it belongs to a class of drugs known as amide local anesthetics. In high doses, or when absorbed into the bloodstream too quickly, lidocaine becomes a potent systemic toxin. It does not just numb the skin; if ingested, it travels through the blood to the central nervous system and the heart.

The core physical failure here is not with the medicine itself, but with the barrier meant to keep it away from those who cannot protect themselves: the packaging. Under normal circumstances, lidocaine products are required by federal law to be in child-resistant containers. These special jars require a specific combination of actions—typically pushing down while turning—to open, which is difficult for small fingers that lack both the strength and the cognitive coordination to perform complex maneuvers. The recalled Mamisan ointment, however, comes in an orange container with a white continuous thread lid. This standard screw-top design opens with simple rotational force, offering no resistance to a curious toddler who can twist it open with ease. Without that crucial mechanical barrier, the high concentration of medication is effectively left within arm’s reach.

When a child swallows even a small amount of this ointment, the harm occurs through a process called systemic absorption. Because the ointment is designed to be applied to the skin, it contains ingredients that help the lidocaine penetrate tissue barriers quickly. If swallowed, this rapid absorption bypasses the liver’s initial filtering process (first-pass metabolism) that would normally break down some of the drug in an adult taking it orally for other reasons. Instead, the lidocaine floods the bloodstream almost immediately. For a small child, whose body mass is significantly lower than an adult’s, even a fraction of the jar can deliver a lethal dose.

The physiological consequences are severe and progress rapidly. Lidocaine interferes with the electrical signals in nerve cells. In the brain, this disruption leads to central nervous system toxicity, which can manifest initially as dizziness, confusion, or seizures. As the drug continues to affect the heart’s electrical conduction system, it can cause fatal arrhythmias—irregular heartbeats that prevent the heart from pumping blood effectively. This can lead to cardiac arrest and death. Because children may not be able to articulate that they feel dizzy or have an upset stomach until the crisis is advanced, the window for emergency intervention is incredibly narrow. The hazard, therefore, is not just that the product is dangerous, but that its packaging invites accidental ingestion by those most vulnerable to its toxic effects.

Who is most at risk

The primary group at immediate and severe risk from this recall consists of young children, particularly those under the age of five. This vulnerability is not merely a statistical likelihood but a fundamental aspect of child development that intersects directly with the specific hazard presented by the Mamisan ointment. At this stage of life, curiosity drives exploration, and the world is understood through tactile interaction and oral ingestion. A child does not distinguish between food, medicine, or household items based on appearance alone; they are drawn to bright colors, accessible shapes, and familiar textures. The recalled Mamisan containers, described as orange plastic jars with white lids, present a visual and physical profile that can be surprisingly inviting to a toddler who is learning to grasp objects and put them in their mouth. Because the packaging lacks child-resistant features, it offers no barrier to this natural behavior, allowing access that should have been physically impossible under federal safety standards.

The danger escalates because of the specific pharmacological properties of lidocaine, the active ingredient in this ointment. Lidocaine is a potent local anesthetic and antiarrhythmic agent. While it is effective for numbing pain on the skin when used as directed, it becomes highly toxic when ingested in quantities appropriate for topical use. Young children have significantly lower body mass than adults, meaning that even a small amount of the ointment—perhaps just a mouthful or two—can deliver a lethal dose relative to their weight. Their developing livers and kidneys are also less efficient at processing and eliminating toxins compared to those of an adult, allowing the drug to accumulate in their system more rapidly. This can lead to serious neurological effects, including seizures, irregular heart rhythms, respiratory distress, and potentially death. The risk is not about accidental misuse by a careless adult; it is about the catastrophic consequence of a child accessing what should have been a secure container.

It is also important to consider the context of the household. This recall affects anyone who uses topical pain relievers for arthritis, muscle strain, or minor injuries. Often, these products are kept in bathrooms, kitchens, or bedside tables where they are visible and within easy reach. For households with grandchildren visiting frequently, the risk may be heightened if caregivers are less familiar with the specific packaging hazards than regular users. The absence of reported incidents to date is reassuring but should not be interpreted as evidence that the product is safe. In cases involving child poisoning, the window for intervention is narrow, and many exposures may go unreported if they are caught early enough by vigilant parents. Therefore, the "at risk" population includes any home where these specific orange jars with UPC code 860006498115 exist, regardless of whether there are currently children present, as visitors or future occupancy can change the risk profile dramatically. The vulnerability lies in the mismatch between the product's accessibility and the severe consequences of its ingestion by those who cannot understand the danger it poses.

How to tell if you have the recalled item

Before you take any action, it is critical to confirm exactly which product is involved in this recall. Not all pain-relieving ointments are affected, and Plantimex has specified a very narrow range of items that pose a risk. The recall applies specifically to jars of Mamisan Pain Relieving Topical Ointment. If you have a different brand or even a different size of Mamisan product, it may not be part of this issue. However, because the packaging is central to the safety hazard, you need to look at several specific physical details on your container to determine if your jar is included.

First, check the shape and material of the container. The recalled items are sold in 3.52-ounce plastic jars. This is a standard size for topical ointments, but the material matters because the recall is about the lid mechanism, not the jar itself holding the ointment. Next, look at the color scheme. The recalled jars have a distinct orange body with a white continuous thread lid. If your jar is a different color, or if the lid is a different style (such as a flip-top or a screw cap that is not white), it is likely not part of this specific recall.

The most reliable way to identify the recalled product is by examining the lid and the label closely. On top of the white lid, you should see the Mamisan trademark printed clearly. Additionally, the jar features a wraparound label that includes drug facts and usage instructions. However, the definitive identifier is the Universal Product Code (UPC). You must locate the barcode on the label or the bottom of the jar. The recall only affects jars with the UPC code 860006498115. If your barcode ends in this specific sequence, your product is part of the recall.

If you have lost the packaging or cannot find the barcode, compare the physical description against the details above: orange plastic jar, 3.52 ounces, white continuous thread lid with Mamisan branding, and the specific UPC code. When in doubt, it is safer to assume it might be recalled and verify by contacting Plantimex directly using the contact information provided in this notice. Do not rely on memory or general appearance alone; the UPC code is your best proof.

What to do — step by step

Your refund, repair, or replacement options

When you receive a notice that a product you own has been recalled due to a safety hazard, the immediate question on your mind is often, "What do I do now?" and "How does this get fixed?" In this specific case involving Plantimex’s Mamisan Pain Relieving Topical Ointment, the remedy is straightforward, but it requires you to take a few specific steps to ensure the issue is resolved correctly. It is important to understand that for this recall, the primary focus is on correcting the safety defect rather than issuing a cash refund. The company has determined that the packaging itself is the problem, not the ointment inside. Therefore, the solution they are offering allows you to keep using the product safely once the hazard is neutralized.

The core of the remedy involves receiving a free replacement lid. Because the recalled jars lack child-resistant packaging, which is required by law for products containing lidocaine, Plantimex is providing new lids that meet these mandatory safety standards. This means you do not need to throw away your current jar of ointment if it is still full or partially full. Instead, you can simply swap out the old, non-compliant white continuous thread lid for the new, safe one provided by the manufacturer. This approach is both environmentally friendly and cost-effective for consumers, as it allows you to continue using a product that may still be effective and within its expiration date, provided you secure it properly in the meantime.

To initiate this process, you must contact Plantimex directly. They have set up several channels for you to reach their customer care team to request your free replacement lid. You can call their toll-free number at 855-752-6869, but please note that they are only available from 9 a.m. to 4 p.m. Pacific Time, Monday through Friday. If you prefer written communication, you can send an email to customercare@plantimexusa.com. When emailing, it is crucial to include the word "RECALL" in the subject line so your request is routed correctly and quickly. Alternatively, you can visit their website at http://plantimexusa.com/contact.php or www.plantimexusa.com to find more information or submit a contact form online.

While you are waiting for your replacement lid to arrive, it is vital that you do not leave the recalled jar where a child could access it. The recall instructions explicitly state that you should immediately secure the ointment jars out of the sight and reach of children. This might mean moving them to a high shelf in a locked cabinet or another area completely inaccessible to young kids. Once your new lid arrives, attach it securely to the jar. After the product is secured with this replacement lid, consumers are cleared to use the product as directed on the label, knowing that the risk of accidental poisoning has been addressed.

If you have already discarded the jar or if it was empty when you received the recall notice, you will not be able to utilize the lid replacement remedy. In such cases, your primary action is simply to confirm that the product is no longer in your home. However, for those who still possess the physical product, engaging with Plantimex through the channels mentioned above is the only way to receive the official remedy. Do not attempt to modify the existing lid yourself or use generic child-proof caps, as these may not meet the rigorous standards required by the Poison Prevention Packaging Act. The free lid provided by Plantimex is specifically designed and tested to comply with federal safety requirements.

It is also worth noting that the recall does not mention a full refund of the purchase price for the ointment itself, only the provision of the corrective part. If you feel the product was defective in other ways unrelated to the packaging, or if you simply no longer wish to use it after securing it with the new lid, your options might be limited to keeping it as a backup or disposing of it safely. However, the official stance from Plantimex is focused on providing the safety component—the lid—to resolve the identified hazard. By following these steps, you ensure that your household remains safe while potentially saving a product that was only compromised by its container.

What can happen if you ignore it

When a product recall involves a medication that is not properly secured, the stakes are fundamentally different from a defective toaster or a torn seam on a jacket. In this specific case with the Plantimex Mamisan Lidocaine Ointment, ignoring the warning to replace the lid is not merely an inconvenience; it is a direct invitation for a potentially fatal accident. The core issue here is that the current packaging fails to meet the mandatory child-resistant standards required by law. This means that the white continuous thread lid on these orange jars can be opened with relative ease by young children who are naturally curious and lack the cognitive development to understand the danger of swallowing medication.

Lidocaine is a powerful local anesthetic, but when ingested orally rather than applied topically, it becomes highly toxic to the central nervous system. Young children have significantly lower body weights than adults, which means even a small amount of this ointment can reach toxic levels in their bloodstream rapidly. If you continue to use the product as-is without securing it with the free replacement lid provided by Plantimex, you are leaving a potent poison within easy reach of toddlers who may mistake the jar for a toy or a container of candy. The risk is not theoretical; it is a well-documented medical emergency scenario.

The consequences of ingestion can be severe and escalate quickly. Immediate symptoms of lidocaine poisoning in children often include drowsiness, confusion, and nausea. However, without immediate medical intervention, these symptoms can rapidly progress to more dangerous conditions such as seizures, irregular heartbeats (arrhythmias), and respiratory depression, where the child’s breathing slows down or stops entirely. In worst-case scenarios, this progression leads to coma and death. Because children can ingest large portions of a jar in a matter of seconds before an adult even realizes they have accessed it, every moment you delay securing the product increases the window of vulnerability.

It is important to note that while no incidents have been reported as of the recall date of December 18, 2025, the absence of reported cases does not mean the risk is absent. It simply means that by sheer luck, no child has yet accessed this specific batch in a dangerous way. Relying on luck is never a safe strategy when dealing with pediatric safety. The packaging violation itself is the proof that the design is insufficient to protect against determined, curious hands. By ignoring the recall, you are effectively gambling with your child’s life, assuming that no one will ever get to the jar again. That is an assumption no parent should make.

Furthermore, there is a secondary risk for older children and adults who might not realize the packaging is non-compliant. If you are storing this ointment in a bathroom cabinet or under a sink where other household cleaners or medications are kept, the lack of child-resistant features makes it indistinguishable from safe products to anyone who is distracted or rushing. This increases the likelihood of accidental ingestion by anyone in the household who does not recognize the danger immediately. The remedy provided by Plantimex is designed to close this gap instantly. Refusing to use it leaves a critical safety barrier removed, turning a manageable home medication into an unsecured hazard.

Staying safe: broader tips

While this specific recall addresses a packaging failure for a topical pain reliever, the underlying principle applies to countless household products that contain potent chemicals or medications. The most effective way to protect your family from accidental poisoning is to assume that any container, regardless of its appearance, can be opened by a determined child. Relying solely on the original manufacturer’s safety features is risky because those mechanisms can wear out, break, or simply fail under pressure. Instead, treat every medicine cabinet, pantry shelf, and bathroom counter as a potential hazard zone that requires active management rather than passive hope.

One of the most critical steps you can take is to never rely on "child-proof" caps as an absolute barrier. These closures are designed to deter young children for a limited time, not to stop them indefinitely. Even if a cap feels difficult to open, it may still be within the physical capability of a toddler who has learned persistence. Always store medications and hazardous household chemicals in high, locked cabinets or dedicated safety boxes that require a key or a complex combination. If you must keep items accessible for quick use, such as allergy medication or first-aid ointments, ensure they are placed on shelves that are completely out of sight and reach—ideally above eye level for an adult and well beyond the climbing range of a child.

Organization plays a surprising role in safety. When products are scattered across multiple surfaces or mixed with non-medical items, it becomes easier to leave them unsecured after use. Establish a dedicated "medicine station" where all drugs, both prescription and over-the-counter, are kept together. This habit ensures that you always return items to their safest location immediately after use. Additionally, be vigilant about what is left in plain sight. Items like colorful vitamin gummies, liquid detergents, and cleaning supplies often mimic the appearance of food or drink, making them particularly tempting to curious youngsters. Keep these items in their original containers with all labels intact; transferring them to other bottles removes vital safety warnings and dosage information.

Finally, make checking for recalls a regular part of your home maintenance routine. Product safety updates happen frequently, and manufacturers often issue voluntary recalls before an incident occurs. You can stay informed by signing up for alerts from the Consumer Product Safety Commission (CPSC) or visiting their website regularly. By staying proactive rather than reactive, you create a safer environment where accidents are prevented through smart storage habits and constant awareness, ensuring that your home remains a place of comfort and security for everyone.